Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
Status:
Completed
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tolerance and efficacy of mobilizing hematopoietic
stem cells after a single injection of plerixafor (0.24mg/kg) in 3 adult patients (or 5, if
results of the first 3 patients are not reproducible) affected by sickle cell disease.